however, it is subject to change
Heres how these medication options compare across both platforms: Disclaimer: Medication availability depends on a licensed clinicians evaluation and prescription
As the demand for innovative, effective treatments for diabetes and obesity continues to rise, the GLP-1 market is expected to expand further, with new drug approvals and improved treatment options likely to drive continued success
The Ozempic GLP-1 MDL added 183 cases between March and April, increasing from 3,363 to 3,546
reduced hunger, from a psychological effect, namely change in cognitions (reduced thinking about food) and affect (reduced anxiety)
Beyond glycaemic control, GLP-1RAs have transformed the pharmacological management of obesity and reshaped current understanding of its pathophysiology